The Technology
We read millions of cells using mass cytometry
Mass Cytometry is a technology used to determine specific properties of cells.
It is an advanced cytometry method that builds upon the established science of flow cytometry while eliminating many of the common challenges associated with the technique.
Armed with in-depth immune information, researchers can make informed decisions around patient response and drive new pathway discoveries.
Mass vs. Flow Cytometry
Mass Cytometry is a technology used to determine specific properties of cells.
It is an advanced cytometry method that builds upon the established science of flow cytometry while eliminating many of the common challenges associated with the technique.
Armed with in-depth immune information, researchers can make informed decisions around patient response and drive new pathway discoveries.
Flow Cytometry
- 10-15 markers per assay
- Significant signal overlap due to fluorescence
- Extensive time to optimization
- Multiple sample consumption for result
MASS Cytometry
- Up to 45 unique markers per assay
- High-resolution, minimal signature overlap
- Reduced time to optimization
- Single sample consumption for result
Expertly Designed Human Pan-Immune Panel
The TokuProfile Human Pan-Immune panel includes:
- Markers to identify every major immune cell population and subsets
- Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
- Markers of recent activation and effector function
- Up to 10 open channels for customization included
-
T cells
- CD3
- Total T cells
- CD4
- CD4+ T cells
- CD8a
- CD8+ T cells
- CD27
- Maturation
- CD45RA
- Naive/Memory
- CCR7 (CD197)
- Naive/Memory
- Foxp3
- Treg
- CD25
- Treg, activation
- CD127
- T cell subsets
- T-bet
- T cell subsets
- CD38
- Maturation
- HLA-DR
- Activation
- TCF1
- Stemness
- CD7
- T cell subsets
- CD56
- NKT, T cell subsets
- gdTCR
- gdT cells
- CTLA-4 (CD152)
- Checkpoint
- PD-1
- Checkpoint
- TIM-3
- Checkpoint
- TIGIT
- Checkpoint
- LAG3
- Checkpoint
-
B cells
- CD19
- Total B cells
- CD25
- Activation
- CD27
- Naive/Memory
- CD38
- Naive/Memory
- HLA-DR
- Antigen presentation
-
NK cells
- CD56
- NK cell subsets
- CD16
- NK cell subsets
- CD8a
- NK cell subsets
- CD7
- NK cell subsets
- CD38
- Activation
- T-bet
- Maturation
-
Myeloid cells
- CD11b
- Monocytes, macrophages
- CD11c
- Monocytes, macrophages, DCs
- CD14
- Monocyte subsets, Macrophages
- CD16
- Monocyte subsets
- CD33
- Total myeloid
- CD123
- pDC
- PD-L1
- Checkpoint ligand
- HLA-DR
- Antigen presentation
-
Granulocytes
Whole blood only- CD11b
- Neutrophils
- CD16
- Neutrophils
- CD123
- Basophils
-
General
- CD45
- Total immune cells
- KI67
- Proliferation
- CD61
- Platelets
- CD235ab
- Erythrocytes
- CD66b
- Granulocytes
- DNA
- Singlets
- Live/Dead
- Viability
-
10 open channels for customization
Turning Data into Insights
CLIA Validation Data
Mass Cytometry Assay for Pan-Immune Profiling of PBMCsFill out the form below to access our CLIA Validation plan, report, and data and SOPs.